Regen® Innovation

RegenKit® Medical Devices were introduced to the U.S.A. in 2010, and we began U.S. Manufacturing in November 2021.  Along with these platforms, and Regen® preparation methods, came the availability of Regen® A-PRP® and Autologous Thrombin Serum (Regen® ATS).

Regen® A-PRP® represents a class of preparations which utilize unique cellular selectivity models to produce RegenPlasma® and RegenCell®.

Learn more about Regen® A-PRP®

Regen® innovative preparation methods have grown into the RegenPRP™ methodology for autologous cellular therapies, though standardization and education.

RegenLab® develops, manufactures, and distributes easy-to-use medical devices, with a focus on patient safety, product quality, biological efficacy, and preparation efficiency.

Our patient-centered technology has led to over two-million treatments provided worldwide, using RegenLab® Medical Device Kits.

In 2021, our U.S. Production facility opened with the purpose of bringing our award-winning products closer to the U.S. market, for purposes of increased patient accessibility.

2023 marked the launch of Regenkit®-Wound Gel

RegenLab®, Regen®, RegenKit®, THT®, RegenPlasma®, RegenCell®, RegenBMC®, VetPRP®, CellularMatrix®, A-PRP® & BioBridge® are U.S. registered trademarks of RegenLab USA and/or Regen Lab SA.

RegenWound™, RegenPRP™, RegenMatrix™, RegenARP™, ArthroVisc™, SkinVisc™, Generation Regeneration™ & RegenVet™ are U.S. pending trademarks of RegenLab USA and/or Regen Lab SA.